Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Companyâs NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individualâs lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
äŒæ¥ã³ãŒãSTIM
äŒç€ŸåNeuronetics Inc
äžå Žæ¥Jun 28, 2018
æé«çµå¶è²¬ä»»è
ãCEOãMr. Keith J. Sullivan
åŸæ¥å¡æ°716
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jun 28
æ¬ç€Ÿæåšå°3222 Phoenixville Pike
éœåžMALVERN
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·19355
é»è©±çªå·18776007555
ãŠã§ããµã€ãhttps://neurostar.com/neuronetics/
äŒæ¥ã³ãŒãSTIM
äžå Žæ¥Jun 28, 2018
æé«çµå¶è²¬ä»»è
ãCEOãMr. Keith J. Sullivan
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã